Skip to main content
Top
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1

Authors: Masoumeh Tavakoli-Yaraki, Fatemeh Karami-Tehrani, Vahid Salimi, Majid Sirati-Sabet

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

15-Lipoxygenase-1 (15-Lox-1) is a key enzyme mediating oxidative metabolism of polyunsaturated fatty acids and has attracted considerable interest as a potential target for the induction of apoptosis in cancer cells. Knowledge of relationship between 15-Lox-1 and histone deacetylase inhibitors is lacking in the breast cancer. This study is aimed to investigate the role of Trichostatin A (TSA) and 13(S)-HODE, as a metabolite of 15-Lox-1, in the regulation of breast cancer cell growth. The cytotoxic effect of TSA, as a potent HDAC inhibitor, was measured using MTT assay. Annexin V–FITC and PI staining were performed to detect apoptosis and cell cycle distribution using Flow cytometry. The role of 15-Lox-1 in the regulation of cell growth was assessed by 15-Lox-1 inhibitor and the level of 15-Lox-1 metabolite was measured to determine 15-Lox activity after treatment by TSA. The results demonstrated that TSA induced cell growth inhibition via 15-Lox-1, in a dose- and time-dependent manner, and subsequently accompanied by the cell cycle arrest and induction of apoptosis. Moreover, growth inhibitory effect of TSA was associated with the elevation of 15-Lox-1 metabolite (13(S)-HODE). This study provided evidences that the inhibitory effect of TSA on the breast cancer cell growth occurs via the induction of 15-Lox-1 activity and 13(S)-HODE production. Our findings underline the possible role of 15-Lox-1/13(S)-HODE pathway as a promising molecular approach for the induction of apoptosis in breast cancer cells.
Literature
1.
go back to reference Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999;274:23679–82.PubMedCrossRef Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999;274:23679–82.PubMedCrossRef
2.
go back to reference Baer AN, Costello PB, Green FA. In vivo activation of an omega-6 oxygenase in human skin. Biochem Biophys Res Commun. 1991;180:98–104.PubMedCrossRef Baer AN, Costello PB, Green FA. In vivo activation of an omega-6 oxygenase in human skin. Biochem Biophys Res Commun. 1991;180:98–104.PubMedCrossRef
3.
go back to reference Brash AR, Jisaka M, Boeglin WE, Chang MS, Keeney DS, Nanney LB, et al. Investigation of a second 15S-lipoxygenase in humans and its expression in epithelial tissues. Adv Exp Med Biol. 1999;469:83–9.PubMedCrossRef Brash AR, Jisaka M, Boeglin WE, Chang MS, Keeney DS, Nanney LB, et al. Investigation of a second 15S-lipoxygenase in humans and its expression in epithelial tissues. Adv Exp Med Biol. 1999;469:83–9.PubMedCrossRef
4.
go back to reference Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: Is the verdict in? Cancer Metastasis Rev. 2011;30:481–91.PubMedCrossRef Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: Is the verdict in? Cancer Metastasis Rev. 2011;30:481–91.PubMedCrossRef
5.
go back to reference Kelavkar U, Glasgow W, Eling TE. The effect of 15-lipoxygenase-1 expression on cancer cells. Curr Urol Rep. 2002;3:207–14.PubMedCrossRef Kelavkar U, Glasgow W, Eling TE. The effect of 15-lipoxygenase-1 expression on cancer cells. Curr Urol Rep. 2002;3:207–14.PubMedCrossRef
6.
go back to reference Nixon JB, Kim KS, Lamb PW, Bottone FG, Eling TE. 15-lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukot Essent Fat Acids. 2004;70:7–15.CrossRef Nixon JB, Kim KS, Lamb PW, Bottone FG, Eling TE. 15-lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukot Essent Fat Acids. 2004;70:7–15.CrossRef
7.
go back to reference Yuan H, Li MY, Ma LT, Hsin MK, Mok TS, Underwood MJ, et al. 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax. 2010;65:321–6.PubMedCrossRef Yuan H, Li MY, Ma LT, Hsin MK, Mok TS, Underwood MJ, et al. 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax. 2010;65:321–6.PubMedCrossRef
8.
go back to reference Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, et al. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis. 1999;20:1985–95.PubMedCrossRef Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, et al. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis. 1999;20:1985–95.PubMedCrossRef
9.
go back to reference Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, et al. Reduced 15 s-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, ns398. Neoplasia. 2003;5:121–7.PubMed Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, et al. Reduced 15 s-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, ns398. Neoplasia. 2003;5:121–7.PubMed
10.
go back to reference Hennig R, Kehl T, Noor S, Ding XZ, Rao SM, Bergmann F, et al. 15-Lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia. 2007;9:917–26.PubMedCrossRef Hennig R, Kehl T, Noor S, Ding XZ, Rao SM, Bergmann F, et al. 15-Lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia. 2007;9:917–26.PubMedCrossRef
11.
go back to reference Jiang WG, Watkins G, Douglas-Jones A, Mansel RE. Reduction of isoforms of 15-lipoxygenase (15-lox)-1 and 15-lox-2 in human breast cancer. Prostaglandins Leukot Essent Fat Acids. 2006;74:235–45.CrossRef Jiang WG, Watkins G, Douglas-Jones A, Mansel RE. Reduction of isoforms of 15-lipoxygenase (15-lox)-1 and 15-lox-2 in human breast cancer. Prostaglandins Leukot Essent Fat Acids. 2006;74:235–45.CrossRef
12.
go back to reference Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, et al. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005;65:11486–92.PubMedCrossRef Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, et al. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005;65:11486–92.PubMedCrossRef
13.
go back to reference Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. 2004;64:8778–81.PubMedCrossRef Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. 2004;64:8778–81.PubMedCrossRef
14.
go back to reference Kim JH, Chang JH, Yoon JH, Lee JG, Bae JH, Kim KS. 15-Lipoxygenase-1 induced by interleukin-4 mediates apoptosis in oral cavity cancer cells. Oral Oncol. 2006;42:825–30.PubMedCrossRef Kim JH, Chang JH, Yoon JH, Lee JG, Bae JH, Kim KS. 15-Lipoxygenase-1 induced by interleukin-4 mediates apoptosis in oral cavity cancer cells. Oral Oncol. 2006;42:825–30.PubMedCrossRef
15.
go back to reference Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, et al. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000;92:1136–42.PubMedCrossRef Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, et al. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000;92:1136–42.PubMedCrossRef
16.
go back to reference Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459–68.PubMedCrossRef Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459–68.PubMedCrossRef
17.
go back to reference Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3:166–79.PubMed Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3:166–79.PubMed
18.
go back to reference Rivera-Del Valle N, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M, et al. PCI-24781, a novel hydroxamic acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol. 2010;2010:207420.PubMed Rivera-Del Valle N, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M, et al. PCI-24781, a novel hydroxamic acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol. 2010;2010:207420.PubMed
19.
go back to reference Margueron R, Duong V, Castet A, Cavailles V. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol. 2004;68:1239–46.PubMedCrossRef Margueron R, Duong V, Castet A, Cavailles V. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol. 2004;68:1239–46.PubMedCrossRef
20.
go back to reference Xiong H, Du W, Zhang YJ, Hong J, Su WY, Tang JT, et al. Trichostatin a, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog. 2012;51:174–84.PubMedCrossRef Xiong H, Du W, Zhang YJ, Hong J, Su WY, Tang JT, et al. Trichostatin a, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog. 2012;51:174–84.PubMedCrossRef
21.
go back to reference Anh TD, Ahn MY, Kim SA, Yoon JH, Ahn SG. The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells. Oncol Rep. 2012;27:455–60.PubMed Anh TD, Ahn MY, Kim SA, Yoon JH, Ahn SG. The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells. Oncol Rep. 2012;27:455–60.PubMed
22.
go back to reference Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001;7:971–6.PubMed Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001;7:971–6.PubMed
23.
go back to reference Schmidt K, Gust R, Jung M. Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch Pharm (Weinheim). 1999;332:353–7.CrossRef Schmidt K, Gust R, Jung M. Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch Pharm (Weinheim). 1999;332:353–7.CrossRef
24.
go back to reference Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, et al. The histone deacetylase inhibitor trichostatin a alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep. 2012;27:10–6.PubMed Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, et al. The histone deacetylase inhibitor trichostatin a alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep. 2012;27:10–6.PubMed
25.
go back to reference Park H, Lee YJ, Kim TH, Lee J, Yoon S, Choi WS, et al. Effects of Trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med. 2008;22:605–11.PubMed Park H, Lee YJ, Kim TH, Lee J, Yoon S, Choi WS, et al. Effects of Trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med. 2008;22:605–11.PubMed
26.
go back to reference Drzewiecka H, Jagodzinski PP. Trichostatin a reduced phospholipase C gamma-1 transcript and protein contents in MCF-7 breast cancer cells. Biomed Pharmacother. 2012;66:1–5.PubMedCrossRef Drzewiecka H, Jagodzinski PP. Trichostatin a reduced phospholipase C gamma-1 transcript and protein contents in MCF-7 breast cancer cells. Biomed Pharmacother. 2012;66:1–5.PubMedCrossRef
27.
go back to reference Zuo X, Morris JS, Shureiqi I. Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. J Biol Chem. 2008;283:31341–7.PubMedCrossRef Zuo X, Morris JS, Shureiqi I. Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. J Biol Chem. 2008;283:31341–7.PubMedCrossRef
28.
go back to reference Zuo X, Morris JS, Broaddus R, Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene. 2009;28:1496–505.PubMedCrossRef Zuo X, Morris JS, Broaddus R, Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene. 2009;28:1496–505.PubMedCrossRef
29.
go back to reference Kamitani H, Taniura S, Ikawa H, Watanabe T, Kelavkar UP, Eling TE. Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. Carcinogenesis. 2001;22:187–91.PubMedCrossRef Kamitani H, Taniura S, Ikawa H, Watanabe T, Kelavkar UP, Eling TE. Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. Carcinogenesis. 2001;22:187–91.PubMedCrossRef
30.
go back to reference Lambrechts S, Decloedt J, Neven P. Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clin Belg. 2011;66:283–92.PubMed Lambrechts S, Decloedt J, Neven P. Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clin Belg. 2011;66:283–92.PubMed
32.
go back to reference Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther. 2003;2:573–80.PubMed Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther. 2003;2:573–80.PubMed
33.
go back to reference Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol. 1997;120:1199–206.PubMedCrossRef Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol. 1997;120:1199–206.PubMedCrossRef
34.
go back to reference Tobaben S, Grohm J, Seiler A, Conrad M, Plesnila N, Culmsee C. Bid-mediated mitochondrial damage is a key mechanism in glutamate-induced oxidative stress and AIF-dependent cell death in immortalized HT-22 hippocampal neurons. Cell Death Differ. 2011;18:282–92.PubMedCrossRef Tobaben S, Grohm J, Seiler A, Conrad M, Plesnila N, Culmsee C. Bid-mediated mitochondrial damage is a key mechanism in glutamate-induced oxidative stress and AIF-dependent cell death in immortalized HT-22 hippocampal neurons. Cell Death Differ. 2011;18:282–92.PubMedCrossRef
35.
go back to reference Lindley AR, Crapster-Pregont M, Liu Y, Kuperman DA. 12/15-Lipoxygenase is an interleukin-13 and interferon-gamma counterregulated-mediator of allergic airway inflammation. Mediat Inflamm. 2010;2010:7273305.CrossRef Lindley AR, Crapster-Pregont M, Liu Y, Kuperman DA. 12/15-Lipoxygenase is an interleukin-13 and interferon-gamma counterregulated-mediator of allergic airway inflammation. Mediat Inflamm. 2010;2010:7273305.CrossRef
36.
go back to reference Cimen I, Tuncay S, Banerjee S. 15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines hct-116 and ht-29. Cancer Sci. 2009;100:2283–91.PubMedCrossRef Cimen I, Tuncay S, Banerjee S. 15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines hct-116 and ht-29. Cancer Sci. 2009;100:2283–91.PubMedCrossRef
37.
go back to reference Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med. 2009;9:565–79.PubMedCrossRef Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med. 2009;9:565–79.PubMedCrossRef
38.
go back to reference Liu C, Schain F, Han H, Xu D, Andersson-Sand H, Forsell P, et al. Epigenetic and transcriptional control of the 15-lipoxygenase-1 gene in a Hodgkin lymphoma cell line. Exp Cell Res. 2011;318:169–76.PubMedCrossRef Liu C, Schain F, Han H, Xu D, Andersson-Sand H, Forsell P, et al. Epigenetic and transcriptional control of the 15-lipoxygenase-1 gene in a Hodgkin lymphoma cell line. Exp Cell Res. 2011;318:169–76.PubMedCrossRef
39.
go back to reference Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, et al. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J. 2008;22:1981–92.PubMedCrossRef Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, et al. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J. 2008;22:1981–92.PubMedCrossRef
40.
go back to reference Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Schneckenleithner C, Wolbank S, et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest. 2011;121:2000–12.PubMedCrossRef Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Schneckenleithner C, Wolbank S, et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest. 2011;121:2000–12.PubMedCrossRef
41.
go back to reference Guo AM, Liu X, Al-Wahab Z, Maddippati KR, Ali-Fehmi R, Scicli AG, et al. Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival. Cancer Chemother Pharmacol. 2011;66:1273–83.CrossRef Guo AM, Liu X, Al-Wahab Z, Maddippati KR, Ali-Fehmi R, Scicli AG, et al. Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival. Cancer Chemother Pharmacol. 2011;66:1273–83.CrossRef
42.
go back to reference Zafiriou MP, Zelarayan LC, Noack C, Renger A, Nigam S, Siafaka-Kapadai A. Hepoxilin A(3) protects beta-cells from apoptosis in contrast to its precursor, 12-hydroperoxyeicosatetraenoic acid. Biochim Biophys Acta. 2011;1811:361–9.PubMedCrossRef Zafiriou MP, Zelarayan LC, Noack C, Renger A, Nigam S, Siafaka-Kapadai A. Hepoxilin A(3) protects beta-cells from apoptosis in contrast to its precursor, 12-hydroperoxyeicosatetraenoic acid. Biochim Biophys Acta. 2011;1811:361–9.PubMedCrossRef
Metadata
Title
Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1
Authors
Masoumeh Tavakoli-Yaraki
Fatemeh Karami-Tehrani
Vahid Salimi
Majid Sirati-Sabet
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0544-7

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine